Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.

British journal of haematology·2026

Same author

Precision medicine in myeloma demands precision imaging: is whole body MRI the solution?

Cancer imaging : the official publication of the International Cancer Imaging Society·2026

Same author

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data.

Clinical pharmacology and therapeutics·2026

Same author

Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum.

Journal of cancer policy·2026

Same author

Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.

HemaSphere·2025

Same author

European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.

HemaSphere·2025

Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 22, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Bone markers in multiple myeloma.

Ulrike Heider¹, Claudia Fleissner, Ivana Zavrski

¹Department of Haematology and Oncology, Charité, Universitätsmedizin Berlin, D-10117 Berlin, Germany.

European Journal of Cancer (Oxford, England : 1990)

|June 13, 2006

Summary

This summary is machine-generated.

Multiple myeloma causes significant bone destruction due to abnormal osteoclast and osteoblast activity. This review discusses biochemical markers for monitoring bone disease activity during treatment.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Feb 22, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

Oncology
Biochemistry
Bone Biology

Background:

Multiple myeloma frequently causes osteolytic bone disease, leading to pain, fractures, and hypercalcemia.
This bone destruction is characterized by bone resorption without adequate bone formation, resulting in extensive lesions.
Current imaging methods like X-rays are insufficient for tracking bone disease activity during treatment.

Purpose of the Study:

To review the pathophysiology of osteoclast activation and osteoblast inhibition in multiple myeloma.
To discuss the utility, prognostic implications, and limitations of biochemical markers of bone turnover.
To highlight the need for effective biochemical markers to monitor myeloma-related bone disease activity.

Main Methods:

Literature review focusing on the pathophysiology of myeloma bone disease.
Analysis of existing research on biochemical markers of bone turnover.
Discussion of classical and novel markers such as ICTP, NTx, TRACP-5b, osteoprotegerin, and sRANKL.

Main Results:

Myeloma bone disease involves dysregulated osteoclast and osteoblast function.
Monoclonal protein levels do not reliably correlate with bone turnover.
Radiological assessment is limited in reflecting dynamic bone disease activity during therapy.

Conclusions:

There is a critical need for reliable biochemical markers to assess myeloma bone disease activity.
Understanding bone turnover markers is essential for effective patient management and treatment monitoring.
Novel markers show promise in providing a more accurate reflection of bone remodeling in multiple myeloma.